A ''suicide'' system based on thymidine kinase -ganciclovir combination was developed and tested in a Leishmania major experimental model. Susceptible BALB/c mice were infected with L. major expressing the thymidine kinase gene of herpes simplex virus type 1 and treated for 2 consecutive weeks with 7.5 mg/kg/day ganciclovir at different times from the initial infection. Ganciclovir treatment at varying times after infection had different effects on the outcome of disease. A complete inhibition of intracellular parasites was obtained in mice treated 1 or 4 days after infection, whereas ganciclovir administration 2 weeks later resulted in the control of infection only when the drug was provided. Variable levels of protection, from partial to total, against challenge infection with virulent L. major were observed, depending on the timing of ganciclovir treatment. The thymidine kinaseganciclovir approach represents an excellent experimental model to control Leishmania infection and to evaluate the immunologic response of the host.
Leishmania parasites belonging to the order Kinetoplastida live recombinant vectors expressing Leishmania antigens [7, 8] , on Leishmania-specific CD4 T cells [9] , or on attenuated are the causative agents of a large spectrum of diseases, varying from localized cutaneous infection to visceral dissemination, parasites obtained by gene replacement [10] . Despite several efforts, no effective vaccine against any form of leishmaniasis which is often fatal if not treated. Leishmaniasis remains a parasitic disease of major importance in several tropical and currently exists in humans. To control Leishmania infections in both murine experimental models and human patients, the subtropical areas, and its control relies on chemotherapy using pentavalent antimony-containing drugs. The effectiveness of development of effective cell-mediated immunity capable of activating macrophages to a microbicidal state is clearly rethese compounds, however, is eroded by the emergence of drug resistance [1] . Therefore, other strategies, such as vaccination, quired [11 -13] .
To identify important parameters for the development of need to be developed for the control of this disease.
Several observations suggest that vaccination against leishprotective immunity following vaccination with live recombinant Leishmania organisms, we have designed a suitable animal maniasis could be feasible. Avirulent temperature-sensitive mutants obtained by chemical mutagenesis, lethally irradiated model system in which the susceptibility to Leishmania infection could be completely reversed by drug treatment capable or heat-killed parasites, or soluble extracts of promastigotes have been used successfully in immunizing mice against cutaof eradicating the parasite. As a result, the animals could then be challenged with infective wild type parasites, and different neous leishmaniasis [2 -5] . More recently, novel approaches aspects of the host immune response could be explored. Our to generate antileishmanial vaccines have been reported. These system is based on the expression of a ''suicide''-type gene were based either on recombinant leishmanial proteins [6] , on by Leishmania organisms, in this case the thymidine kinase gene of herpes simplex virus type 1 (HSV-1 tk), which phosphorylates ganciclovir, a nucleoside analogue, into a highly takes place, a single dose of 5 mg/kg containing 0.02 mCi of [8-in Trypanosoma brucei [26] . Recently the wild type and transfected L. major cell lines were freshly Parasites were grown in SDM-79 medium [27] supplemented with isolated from mice to maintain virulence. BALB/c mice are geneti-10% fetal bovine serum (Multicell; Wisent Canadian Laboratories, cally susceptible to L. major infection [30] , as they fail to control St-Bruno, Canada) and 5 mg/mL hemin. L. major-tk recombinant cutaneous infection at the level of footpad, and they usually unparasites, expressing the tk gene of HSV-1, and L. majordergo fatal dissemination to the liver and the spleen over a few pSPYneo, expressing the neomycin phosphotransferase gene weeks after parasite inoculation [31] . Cutaneous infection in mice (neo), were generated by transfection of vectors pneotk-2 [15] and was monitored by measuring the thickness of inflated footpads pSPYneo [28] , respectively, into L. major LV39. Transfections with a metric caliper at weekly intervals. The net value for the were done as described previously [29] , and transfectants were footpad thickness (in millimeters) was calculated by subtracting selected and grown in the presence of 40 mg/mL G-418 (Geneticin; the diameter of the noninfected footpad from the diameter of the Life Technologies GIBCO BRL, Gaithersburg, MD). In vector infected footpad. Treatment with ganciclovir was started at days pneotk-2, the expression of tk gene is driven by a 92-bp synthetic 1, 4, or 14 after initial inoculation of the parasites and continued polypyrimidine stretch followed by an AG splicing acceptor site for 2 consecutive weeks at total dose of 7.5 mg/kg/day ip. The [28] .
optimal dose of ganciclovir was determined from the pharmacokiPharmacokinetics. A single dose of ganciclovir (Cytovene; netic studies done in BALB/c mice. Placebo control animals were Syntex, Mississauga, Canada) was administered to female BALB/ treated with PBS under the same conditions as those for ganciclovir c mice (age, 6-8 weeks; weight, 18-20 g) either intraperitoneally administration. Treated mice that did not develop any cutaneous (ip) or subcutaneously (sc) in the upper back below the neck. Each lesion at the level of footpad were challenged 2 weeks after the animal received a bolus dose of 5 mg of ganciclovir/kg containing end of the treatment with 10 7 virulent L. major LV39 parasites. 0.02 mCi of [8-3 H]ganciclovir (Moravek Biochemicals, Brea, CA), Protective index to reinfection was monitored by weekly measureand the injection volume was Ç0.3 mL. At designated time points ment of the footpad swelling with a metric caliper for a period of (0, 1, 2, 4, 8, 16, 30, 60, and 120 min), 40-50 mL of blood 12 weeks. was collected via the retroorbital sinus of mice and separated by DNA manipulations. Total genomic DNA from Leishmania centrifugation (6000 g for 10 min at 20ЊC). The pharmacokinetic organisms was prepared as described [32] , digested with BglII, parameters for each mouse were determined by using a noncomresolved on a 0.7% agarose gel, and transferred to a nylon mempartmental model. The elimination rate constant (K el ) was estibrane (Hybond-N; Amersham Canada, Oakville, Canada). Southmated from the slope of the terminal elimination phase of the ern blots and hybridizations were done following standard proceplasma concentration-time curve. The half-life in plasma of the dures [33] . Washings were done at high stringency in 31 standard terminal elimination phase (t 1/2 ) was calculated as 0.693/K el . The saline citrate (SSC)-0.1% SDS and in 0.11 SSC-0.1% SDS at area under the plasma concentration-time curve (AUC 0-ϱ ) and 65ЊC. The tk-specific probe used corresponds to a polymerase the area under the first moment of the concentration-time curve chain reaction fragment generated as reported previously [15] . (AUMC 0-ϱ ) were calculated by using the log-trapezoidal rule with Trypanothione reductase was used as a single-copy gene probe. the terminal portion extrapolated to infinity. The systemic clearThis probe was made by polymerase chain reaction as deance was calculated as dose/AUC 0-ϱ , while the mean residence scribed [34] . time was calculated as AUMC 0-ϱ /AUC 0-ϱ . The maximum drug concentration in plasma (C max ) and the time when C max was obtained were evaluated by visual inspection of the plasma concentra- eliminate the parasites expressing the tk gene by ganciclovir organisms (data not shown). Therefore, our data on ganciclovir pharmacokinetics have clearly indicated that the two routes of treatment in infected animals, we first had to establish the pharmacokinetics for this drug. To evaluate the optimal route administration of ganciclovir were suitable in both infected and uninfected mice. for ganciclovir delivery into BALB/c mice, the drug was administered either ip or sc. No significant differences in serum As L. major infection in BALB/c mice initially develops at the level of the footpad, where parasites are injected sc, we ganciclovir levels were observed between ip and sc administration of the drug at different time intervals up to 120 min. The considered it important to evaluate the ganciclovir concentration that could be accumulated in infected versus uninfected concentration-time curve of ganciclovir in serum was monitored with a radioactive tracer ([8- footpads. Therefore, a single dose of [8-3 H]ganciclovir was injected sc into 2 groups of 5 mice with infected and uninfected The pharmacokinetic parameters of both ip and sc administration of ganciclovir are presented in table 1. These parameters footpads. Ganciclovir accumulated more in infected footpads than in uninfected ones: mean { SE, 13.45 { 2.04 mg/mL were evaluated for each mouse by use of a noncompartmental model. For both routes of administration, the t 1/2 was 1.5 h and versus 8.67 { 1.20 mg/mL. The ratio of ganciclovir in infected to uninfected footpads was 1.63 { 0.17 (the weight ratio of the time taken to reach C max was 3.2 h, as calculated by visual inspection of the plasma concentration-time curve of each infected to uninfected footpads was 1.69 { 0.09). Although the difference in ganciclovir accumulation between the 2 groups of mouse (table 1). The slopes that represent the elimination part of ganciclovir and the systemic clearance also remained similar animals was not very high, it was statistically significant as calculated by use of a nonparametric Mann-Whitney rank sum in both groups (table 1) . To test whether differences in the pharmacokinetics of ganciclovir may have occurred when it test. Specific killing of L. major expressing the tk gene in mice was administered into infected mice, similar experiments were done with a set of infected animals. The pharmacokinetics of is mediated by ganciclovir treatment. We showed recently that Leishmania organisms expressing the HSV-1 tk gene in ganciclovir were similar in animals infected by Leishmania Table 1 . Pharmacokinetic parameters of intraperiteonal (ip) and subcutaneous (sc) administration of 5 mg/kg ganciclovir in BALB/c mice. consecutive weeks was initiated at day 1, 4, or 14 after the injection of tk-expressing L. major parasites into BALB/c mice. Depending on the postinfection time at which the ganciclovir treatment was initiated, the effect of the drug on parasite elimination was different. When treatment was started 1 or 4 days after infection, no sign of inflammation or of cutaneous lesion was detected, even after 12 weeks, compared with the group of animals treated with PBS (figure 2; data not shown). Clearly, ganciclovir administration within the first days following L. major -tk inoculation into BALB/c mice allows complete elimination of the parasite. However, when ganciclovir treatment in mice was started 14 days after inoculation of the parasites, the inflammation at the level of footpad regressed and remained stable as long as the drug was administered, but infection started to progress 1 -2 weeks after the drug was discontinued (figure 2). To explain To evaluate whether the successfully treated mice had also developed an effective immune response capable of ensuring protection against reinfection, we challenged these animals with a virulent L. major strain. Two weeks after the end of ganciclovir administration, we inoculated sc virulent L. major parasites into the same footpads that were initially infected with the tk-expressing L. major strain. A group of naive mice was also infected with the same virulent strain to follow To assess the importance of the route of infection on the overall protective index to reinfection, we injected a group of demonstrated the usefulness and effectiveness of this system in an experimental murine model, in which infection with live mice iv into the tail vein with tk-expressing L. major parasites and started the ganciclovir treatment 4 days after inoculation recombinant parasites expressing the tk gene under ganciclovir treatment allowed the development of a protective immune as described above. These mice were then challenged with virulent L. major parasites inoculated sc into the footpad. Ten response. The rationale of this approach is based on the ability of the tk gene of HSV-1 to convert nucleoside analogues, such weeks after L. major infection in mice, we did not detect any inflammation at the level of footpad or any parasitic burden in as ganciclovir, to toxic nucleotide intermediates. The activation of these compounds as a consequence of tk expression disrupts spleen or liver tissues, as determined by the limiting dilution assay [35] . Our results suggest, therefore, that comparable levcellular DNA replication, leading to cell death [16 -18] .
We have first focused on L. major infection in BALB/c els of protection against infectious challenge can be obtained in animals vaccinated by either the iv or sc route (figure 4). susceptible mice. These studies have permitted us to optimize our animal model and to test whether recombinant parasites maintained their infectivity and whether episomal vectors transDiscussion fected into Leishmania organisms were retained once inside animals without any drug selection. Our data suggest that transThe HSV-1 tk gene has been used recently as a negative selectable marker in both stages of the life cycle of several fection did not alter parasite infectivity and that recombinant Leishmania organisms isolated from infected footpads have Leishmania species [14, 15] . In this work, we have evaluated the potential of using the combination tk-ganciclovir system as maintained episomal vectors several weeks after infection (figure 3). part of a theoretical vaccination strategy approach. We have / 9d3d$$ja27
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Mice inoculated with L. major expressing the tk gene and tion is probably associated with the state of the host immune response. Several therapeutic interventions associated with the treated with ganciclovir for 2 consecutive weeks did not develop any cutaneous lesions when treatment was started 1 or development of a Th1 response have been shown to be effective only when administered within the first week of infection [39, 4 days after parasite infection into mice (figure 2). However, when the ganciclovir treatment was initiated 14 days from the 40] , and these data are in line with our hypothesis. It is also possible that the continuous stimulation of the immune system beginning of infection, a regression of the inflammation of the footpad was observed only during ganciclovir treatment, as by the parasite during these 14 days could induce an important inflammatory reaction, resulting in the migration of a number infection began to progress 1 -2 weeks after the end of drug administration (figure 2). We have investigated two possibiliof molecules, such as chemokines and others, at the site of infection. This could create a microenvironment that may interties in trying to explain the persistence of parasites in this group of mice: first, loss of the tk expression vector with time, fere either with the efficiency of the drug to penetrate macrophages or with its activity, explaining in part why the drug and second, mutations within the tk gene. Both could explain the reemergence of parasites and the appearance of cutaneous alone under this context could not efficiently eliminate all of the parasites. Nevertheless, as infection was controlled under lesions Ç2 weeks after discontinuation of ganciclovir treatment. As demonstrated above, neither of these possibilities the period of ganciclovir treatment, this hypothesis is less likely. turned out to be correct ( figure 3; data not shown) .
If the failure to control L. major infection in mice treated Resistance to challenge with virulent L. major wild type was observed in mice treated 1 or 4 days after infection, and this with ganciclovir 14 days after inoculation was due to the emergence of parasites lacking the tk expression vector, one should was seen whether parasites were initially inoculated sc or iv (figure 4). Variable levels of protection were detected between expect these parasites to represent the majority of the cells found in the infected footpads at weeks 6 and 10; this was the 2 groups of vaccinated animals, however. Mice treated 4 days after infection were the ones that developed probably the clearly not the case, as shown by the hybridization results in figure 3 . Moreover, in several recent experiments, we have best protective immunity, as they were completely resistant to infective challenge with a virulent L. major strain (figure 4). grown recombinant parasites freshly isolated from footpads in the absence or presence of the selective drug G418. No signifiThese results are supported by previous reports showing that L. major promastigotes stimulate a vigorous cytokine response cant differences in the growth rate were noted, suggesting that the loss of the vector, at least during a short period of time, is in CD4 T cells, draining the site of inoculation, and that this response is maximal after 4 days following the infection in mice not significant. These results are supported by previous data from our laboratory, in which we showed that episomal vectors [41] . Early treatment probably helps to eliminate the parasites before the commitment to the Th2 phenotype, which occurs in axenic Leishmania cultures were maintained for several months without any drug selection [28] . However, variation in by the end of the first week depending on the susceptibility background of the mice [38, 41] . However, when ganciclovir the copy number of the tk vector among Leishmania cells that are part of the same population cannot be excluded, and this treatment was started 1 day after the parasite inoculation, immunization was partial, as animals initially developed a local could influence the efficiency of ganciclovir to rapidly eliminate the parasite. Nevertheless, the copy number of the plasmid inflammation but thereafter succeeded in controlling the infection (figure 4). We attribute this difference between the 2 at week 6 (figure 3) was high enough to ensure ganciclovir efficiency. To avoid potential problems with episomal vector groups of vaccinated mice to the faster eradication of the parasites in animals treated at day 1 compared with those treated stability, however, especially when animals have to be manipulated for a longer period of time, it may be advantageous to 3 days later. The presence of a lower parasite burden within the very first days of the infection because of the early ganciclovir integrate the tk gene into the genome by using gene targeting technologies as a way to preserve the ganciclovir susceptibility effective treatment could possibly affect the maximal recognition of leishmanial antigens, resulting in the development of a phenotype. Our results suggest, therefore, that ganciclovir treatment started 14 days after infection, although it was controlling less efficient immune response that, nevertheless, in our case, has succeed in controlling the infection in mice. Immunization parasite growth as long as it was being administered, was not sufficient to clear L. major infection in BALB/c mice, and this of susceptible BALB/c mice against infective challenge by using a low dose of L. major parasites has already been reported was not mainly due to loss of the tk plasmid or to mutations.
It has been clearly established that the capacity to resolve by Bretscher et al. [42] . Overall, the results we have obtained on the effect of the timing of ganciclovir treatment on the Leishmania infection in both mice [36] and humans [37] requires the development of CD4 T cells. In an L. major experidevelopment of a protective immunity allow us to suggest that elimination of the tk-expressing parasites occurs with ganmental model, it has been shown that in BALB/c susceptible mice, the expansion of the Th1 CD4 healer phenotype is overciclovir treatment in conjunction with an effective immune response from the host, as evidenced by the mice whose treattaken in the second week by Th2, a nonhealer phenotype [38] . We propose that the progress of L. major infection in susceptiment was begun on day 14, in which ganciclovir alone was not sufficient to clear the parasites (figures 2 and 4). ble mice treated with ganciclovir 2 weeks after parasite inocula-/ 9d3d$$ja27
